Niagen Bioscience, Inc. (NAGE) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001386570 · SEC filings checked Oct 17, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | $29.8M | $963,000 | $0.01 | Filing |
| Mar 31, 2026 | May 6, 2026 | $31.5M | $6.3M | $0.07 | Filing |
| Dec 31, 2025 | Mar 4, 2026 | $33.8M | $4.1M | $0.05 | Filing |
| Sep 30, 2025 | Nov 4, 2025 | $34.0M | $4.6M | $0.05 | Filing |
| Jun 30, 2025 | Aug 6, 2025 | $31.1M | $3.6M | $0.04 | Filing |
| Mar 31, 2025 | May 7, 2025 | $30.5M | $5.1M | $0.06 | Filing |
| Dec 31, 2024 | Mar 4, 2025 | $29.1M | $7.2M | $0.10 | Filing |
| Sep 30, 2024 | Oct 31, 2024 | $25.6M | $1.9M | $0.02 | Filing |
What would Niagen Bioscience, Inc. have to report for its valuation to change?
At $2.49, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 3.4% a year, to $0.21. On that path the next quarter needs diluted EPS near $0.05, against $0.05 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 3.4% | 3.4% |
| EPS needed in final year | $0.21 | $0.21 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. NAGE goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.